/ 2 items

#NEUP↓

NEUP/ 11/11/2025 · 8:16 AM

Neuphoria Explores Sale Options After Drug Trial Failure

Neuphoria Therapeutics initiates strategic review following failed clinical trial. Lynx1 Fund offers $5.20/share buyout as biotech company explores merger and partnership options.

NEUP/ 10/20/2025 · 5:15 PM

Neuphoria's Social Anxiety Treatment Fails Phase 3 Trial

Neuphoria's AFFIRM-1 Phase 3 trial for BNC210 social anxiety treatment misses all endpoints. Company halts SAD program, reviews options.